FDA Finds No Cancer Link for Ezetimibe or Simvastatin

A review of data from three studies indicates that simvastatin, ezetimibe, or the combination of the two are not likely to be increase the risk of cancer or death from cancer, but that the association cannot be “definitively ruled out,” the Food and Drug Administration announced.